AstraZeneca PLC (AZN) Is A Stock You Should Watch


As of Friday close, AstraZeneca PLC’s (NASDAQ:AZN) stock was down -$0.37, moving down -0.56 percent to $65.61. The average number of shares traded per day over the past five days has been 5,664,400 shares. 2 times new highs have been achieved over the past 5 days, with a $1.42 gain in that time frame. In the last twenty days, the average volume was 4,309,965, while in the previous 50 days, it was 5,374,254.

Since last month, AZN stock retreated -5.85%. Shares of the company fell to $63.77 on 03/08/23, the lowest level in the past month. A 52-week high of $72.12 was reached on 01/10/23 after having rallying from a 52-week low of $52.65. Since the beginning of this year, AZN’s stock price has dropped by -3.23% or -$2.19, and marked a new high 5 times. However, the stock has declined by -9.03% since its 52-week high.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


Valuation Metrics

Right now, AstraZeneca PLC (AZN) has a P/E ratio of about 62.25. The stock’s beta is 0.53. Besides these, the trailing price-to-sales (P/S) ratio of 4.60, the price-to-book (PB) ratio of 5.49, and the price-to-cash flow ratio of 46.83 may also be considered.

The latest dividend of $0.9850 per share was paid out, which is 111.83% more than last year’s $0.4650. On Thursday February 9 2023, a $0.52 dividend increase was announced.

Financial Health

In the three months ended December 30, AstraZeneca PLC’s quick ratio stood at 0.70, while its current ratio was 0.90, showing that the company is not able to pay off its debt. According to company report, the long-term debt-to-equity ratio for the quarter ending December 30 was 0.64, and the total debt-to-equity ratio was 0.79. On the profitability front, the trailing twelve-month gross margin is 80.10% percent. In the year ended December 30, EBITDA margin amounted to 23.26%, whereas operating margins totaled 8.50%. Based on annual data, AZN earned $31.96 billion in gross profit and brought in $44.35 billion in revenue.

A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was 6.90%. Return on equity (ROE) for the past 12 months was 9.10%.

According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. AZN’s revenue rose 15.63% during the quarter, while net income inched up to $44.35 billion. While analysts expected AstraZeneca PLC to report $0.67 quarterly earnings, the actual figure was $0.69 per share, beating the consensus estimate by 3.00%. During the quarter, the company generated $2.58 billion in EBITDA. The liabilities of AstraZeneca PLC were 59.42 billion at the end of its most recent quarter ended December 30, and its total debt was $29.49 billion.

Technical Picture

This quick technical analysis looks at AstraZeneca PLC’s (AZN) price momentum. With a historical volatility rate of 14.78%, the RSI 9-day stood at 51.46% on 17 March.

With respect to its five-day moving average, the current AstraZeneca PLC price is up by +2.21% percent or $1.42. At present, AZN shares trade -3.44% below its 20-day simple moving average and +19.36% percent above its 100-day simple moving average. However, the stock is currently trading approximately -5.60% below its SMA50 and -1.31% below its SMA200.

Stochastic coefficient K was 57.10% and Stochastic coefficient D was 41.74%, while ATR was 1.10. Given the Stochastic reading of 79.65% for the 14-day period, the RSI (14) reading has been calculated as 48.45%. As of today, the MACD Oscillator reading stands at 0.60, while the 14-day reading stands at 0.50.

Analyst Ratings

BMO Capital Markets launched its rating on AstraZeneca PLC (NASDAQ: AZN) to an Outperform in a note to investors on January 05, 2023. AstraZeneca PLC (AZN) has been rated Overweight by analysts. According to 0 brokerage firms, AZN is a sell, and 6 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 3 analysts rate AstraZeneca PLC stock as buy, with 21 recommending it as overweight.

With a median target price of $77.21, the current consensus forecast for the stock is $64.32 – $105.26. Based on these forecasts, analysts predict AstraZeneca PLC (AZN) will achieve an average price target of $78.56.


Please enter your comment!
Please enter your name here